Compare · CDNA vs ELV
CDNA vs ELV
Side-by-side comparison of CareDx Inc. (CDNA) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDNA and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $81.74B, about 76.0x CDNA ($1.08B).
- Over the past year, CDNA is up 38.5% and ELV is down 7.8% - CDNA leads by 46.3 points.
- CDNA has been more active in the news (17 items in the past 4 weeks vs 7 for ELV).
- ELV has more recent analyst coverage (22 ratings vs 18 for CDNA).
- Company
- CareDx Inc.
- Elevance Health Inc.
- Price
- $20.79+0.56%
- $376.62-0.02%
- Market cap
- $1.08B
- $81.74B
- 1M return
- +19.73%
- +28.60%
- 1Y return
- +38.47%
- -7.78%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 17
- 7
- Recent ratings
- 18
- 22
CareDx Inc.
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest CDNA
- SEC Form S-3ASR filed by CareDx Inc.
- SEC Form 10-Q filed by CareDx Inc.
- CareDx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Regulation FD Disclosure, Entry into a Material Definitive Agreement, Other Events
- CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
- CareDx Announces First Quarter 2026 Financial Results
- SEC Form DEFA14A filed by CareDx Inc.
- SEC Form DEF 14A filed by CareDx Inc.
- Amendment: CareDx Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 4 filed by Kennedy Keith
- SEC Form 4 filed by Hanna John Walter Jr
Latest ELV
- Elevance Health's Affiliated Health Plans Deliver More Predictable, Lower Healthcare Costs for Small Businesses
- Elevance Health upgraded by BofA Securities with a new price target
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports First Quarter 2026 Results; Raises Full-Year Guidance
- Evercore ISI initiated coverage on Elevance Health with a new price target
- SEC Form PX14A6G filed by Elevance Health Inc.
- Elevance Health Announces Leadership Appointments to Strengthen Execution and Drive Growth
- Elevance Health to Hold Conference Call and Webcast to Discuss First Quarter 2026 Results on April 22, 2026
- SEC Form DEFA14A filed by Elevance Health Inc.